Dapsone is named as an intervention in 2 current clinical trials in our Canada, Japan and Egypt registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is University of Pennsylvania (1). The most-studied condition is Primary Cutaneous Vasculitis.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Randomized Multicenter Study for Isolated Skin Vasculitis
NCT02939573 · ClinicalTrials.gov ↗ · Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis
|
Phase 2 | Recruiting | University of Pennsylvania | Canada, Japan |
|
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients
NCT06819449 · ClinicalTrials.gov ↗ · Leprosy, Mycobacterium Leprae Infection
|
Not applicable | Recruiting | South Valley University | Egypt |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
| Lead sponsor | Trials |
|---|---|
| University of Pennsylvania | 1 |
| South Valley University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Japan | 1 | 1 |
| Clinical trials in Egypt | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Canada, Japan and Egypt registers name Dapsone as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in Canada, 1 with sites in Japan and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
University of Pennsylvania (1) and South Valley University (1). The number in brackets is how many trials each organisation leads.
The registers we track list 1 entry for Dapsone: 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Dapsone works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Dapsone works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Dapsone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.